Skip to main content

Table 1 Demographic/Clinical Characteristics (6 month pre-period)

From: Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study

Characteristic Infliximab (N = 598) Etanercept (N = 950)
Age (%)   
   < 18 0.2 4.1
   18 – 34 7.0 8.7
   35 – 44 19.9 23.3
   45 – 54 35.8 37.2
   55 – 64 32.4 25.1
   65 + 4.7 1.7
Age   
   Mean 50.5 46.6
   SE 0.4 0.4
   Min 16 2
   Max 80 88
Gender (% female) 76.4 72.1
Plan Type (%)   
   HMO 29.8 44.8
   PPO 48.7 34.5
   POS 12.5 16.3
   Indemnity 7.5 2.6
   Other 1.5 1.7
Geographic Region (%)   
   East 8.7 15.7
   South 45.0 15.9
   Midwest 38.8 57.4
   West 7.5 11.1
Physician Specialty (%)   
   FP/GP 6.4 3.4
   Internal Medicine 3.5 3.8
   Rheumatology 52.7 64.1
   Other 27.6 18.8
   Unknown 9.9 9.9
Infusions/Rxs (Infliximab/Etanercept)   
   Mean 7.0 10.4
   Median 7.5 11.0
   SD 2.1 3.8
Pre-index Therapies (%)   
   NSAID 26.3 41.6
   Cox-II 27.1 34.5
   Other Misc. Anti-inflammatory 1.3 3.2
   Gold Compound 2.7 3.3
   Methotrexate 56.5 55.2
   Leflunomide 19.4 25.9
   Other DMARD 20.7 26.6
   Other RA related therapy 74.9 78.8
Pre-index Medical Diagnoses (%)   
   Osteoporosis 9.2 7.5
   Depression 3.8 3.2
Selected Pre-index Procedures (%)   
   Joint Aspiration/Injection Procedures 34.6 27.7
   Synovectomy 0.7 0.7
   Arthroplasty 1.5 0.8
   Arthrodesis 0.7 0.9
   Arthroscopy 0.8 1.4
   Liver Function Tests 42.5 54.5
   Urinalysis 31.3 33.8
   Hematologic/Serologic Tests 81.3 75.8
   Bone/Joint Imaging 33.8 31.5
   Centesis Procedures 24.1 20.9
   Upper Respiratory Infections 5.7 5.8
   Chest X-ray 21.4 17.3
Pre-index Total Healthcare Costs ($)   
   Mean 3,916.40 3,585.11
   SE 225.46 252.39
   Min 60.23 0.00
   Max 47,306.12 178,388.26